Vice President, Strategy & Business Development - Advanced Therapeutics Division

• Own the full P&L and overall performance of ATD, with accountability for revenue growth, pr ofitability, margin expansion, cash generation and return on invested capital.
• Set and continually evolve the multiyear growth agenda, translating strategy into focused operating priorities, resource choices and measurable outcomes.
• Establish a rigorous operating cadence using data, KPIs and leading indicators across commercial pipeline, program execution, productivity, innovation, quality and financial performance; balance near-term delivery with long-term investment.

• Own the global business-development strategy and revenue opportunity pipeline end-to-end, from market development and lead generation through qualification, contracting, program award, scale-up and commercial handoff.
• Build a systematic, data-driven commercial engine that improves pipeline quality, deal velocity, conversion, forecast accuracy and expansion within strategic accounts.
• Develop deep relationships with senior pharmaceutical and biotechnology decision makers, personally lead the most consequential opportunities, and ensure customer commitments align with capability, capacity, quality, capital needs and long-term economics.

• Build durable alliances with key customers, technology partners and platform collaborators, positioning Agilent as a preferred development and manufacturing partner.
• Develop a high-value network of scientific leaders and key opinion leaders and represent Agilent with authority at major customer engagements, industry forums and scientific conferences.
• Create mechanisms that translate external customer, scientific and market insight into portfolio, R&D and investment decisions.

• Define short- and long-term portfolio strategy across RNA oligonucleotides, BioVectra and relevant adjacent modalities, identifying where Agilent can build differentiated and defensible leadership positions.
• Oversee early-stage R&D and technology investment priorities, ensuring innovation addresses important customer problems and commercially attractive emerging modalities.
• Own strategic marketing, segmentation, positioning and market development; assess modality mix, service-line expansion, capacity needs and technology evolution to determine where to invest, partner, acquire or deprioritize.

• In close collaboration with Global Operations, drive the strategic capital-allocation agenda across manufacturing capacity, technology platforms, R&D and commercial capability using disciplined strategic and financial criteria.
• Identify and develop acquisitions, partnerships, licensing opportunities and other strategic investments; build compelling business cases and secure alignment across Agilent leadership, Finance and Corporate Development.
• Co-lead the strategic and organizational integration of acquired businesses and capabilities, with accountability for realization of the growth and value-creation thesis.

• Lead and develop a geographically distributed, cross-functional organization spanning portfolio strategy, business development, early R&D, marketing and support functions.
• Create shared purpose and increasing integration across the Colorado and BioVectra businesses while preserving the speed, expertise and customer responsiveness required in CDMO markets.
• Build alignment across a complex global matrix and partner closely with Operations, Quality, Regulatory, Finance, HR, Legal, Corporate Development and other enterprise functions.
• Attract and develop exceptional talent, build succession depth and create a culture of customer focus, accountability, collaboration, scientific curiosity and continuous improvement through periods of growth and change.

Measures of Success

• A qualified and predictable opportunity pipeline that delivers targeted conversion, new program wins, customer retention and strategic-account expansion.
• Achievement of revenue growth, margin and return targets in partnership with division and operations leadership.
• A clear, prioritized portfolio and innovation agenda aligned with differentiated market opportunities and disciplined organic and inorganic investment decisions.
• Customer commitments and growth priorities aligned with capacity, technical delivery, quality requirements and sustainable long-term economics.
• An integrated organization with effective cross-functional collaboration, succession coverage for critical roles and external recognition as a preferred advanced therapeutics partner.

Qualifications

The ideal candidate is a proven enterprise leader with deep strength in commercial lead generation and portfolio strategy, supported by scientific and technical fluency, financial discipline and a strong connection to operations. The role does not require prior full P&L or direct operations ownership, but it does require evidence that the candidate can make sound growth decisions in a complex development and manufacturing environment.

Experience

• 15 or more years of progressive leadership experience in CDMO, biopharma manufacturing, life-sciences tools or services, or a closely related sector, including significant executive responsibility.
• Demonstrated accountability for commercial growth and meaningful financial outcomes at scale. Full P&L ownership is preferred; comparable responsibility for a major business, portfolio, commercial function or growth agenda will also be considered.
• Broad and deep understanding of pharmaceutical and biotechnology customers and the scientific, regulatory, quality and economic dynamics of development and manufacturing.
• Relevant exposure to nucleic-acid therapeutics, oligonucleotides, RNA, biologics, APIs, peptides, complex chemistry or other advanced therapeutic modalities; direct oligonucleotide experience is highly desirable.
• Demonstrated success in business development, strategic-account leadership and the creation and conversion of complex, high-value revenue pipelines.
• Meaningful leadership across portfolio strategy, strategic marketing, early R&D or technology choices, with a record of translating market insight into clear investment priorities.
• Clear operational fluency and credibility, including an understanding of capacity, technical transfer, program delivery, quality, productivity and capital tradeoffs.
• Direct experience with major organic capital decisions and meaningful involvement in M&A, partnerships, diligence and integration.
• Proven ability to integrate resources across a large, global matrix and influence executive stakeholders who are not direct reports.